IgE Epitope-Like Peptides for Peanut Allergy Degranulation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergen-specific immunotherapy (AIT) methods for peanut allergy are limited by severe systemic adverse events and low efficiency, with no approved therapies, and existing hypoallergen approaches fail to induce effective immune tolerance, posing a significant public health concern.
Innovation Solution
Development of IgE epitope-like peptides that bind to peanut-specific IgEs on effector cells, preventing cross-linking by causative allergens and thereby inhibiting degranulation and mediator secretion, offering a novel therapeutic strategy for peanut allergy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional allergen-specific immunotherapy (AIT) is administered to induce immune tolerance, then long-term disease modifying effect is achieved, but severe systemic adverse events including anaphylaxis occur
Solution Approach 1:
The patent segments the allergen into small peptide fragments (5-20 amino acids) that represent specific IgE epitopes. These segmented peptides are presented to the immune system separately rather than as complete allergen proteins, allowing selective targeting of IgE responses without triggering full allergen-mediated anaphylaxis. This segmentation enables immune tolerance induction while reducing systemic adverse events.
Solution Approach 2:
The patent extracts specific IgE-binding epitope sequences from complete allergen proteins. By isolating and using only these critical peptide fragments (such as Ara h 2 epitopes for peanut allergy), the therapy removes the harmful components (full allergen proteins that cause anaphylaxis) while retaining the therapeutic elements (epitopes that drive IgE responses). This extraction approach achieves tolerance induction without severe adverse events.
2Reliability
If crude allergen extracts are used for AIT, then allergen-specific immune response is stimulated, but standardization is difficult and de novo IgE sensitization occurs
Solution Approach 1:
The patent creates simplified copies of the critical IgE-binding epitopes using synthetic peptide technology. Instead of using complex crude allergen extracts with variable compositions, the invention synthesizes precise copies of the essential epitope sequences (e.g., specific Ara h 2 peptide fragments). These synthetic peptide copies can be manufactured with high precision, consistent purity, and exact sequence control, eliminating standardization issues while maintaining immune response stimulation.
3Manufacturing precision
If recombinant allergens are used in AIT, then defined immunological properties are achieved, but similar to natural allergens they induce unwanted adverse events
Solution Approach 1:
The patent extracts only the essential IgE-binding epitope fragments (5-20 amino acids) from complete recombinant allergen proteins. By using these truncated peptide sequences rather than full-length recombinant allergens, the therapy maintains defined immunological properties (specific IgE epitope recognition) while removing the portions of the allergen that trigger unwanted adverse events. This extraction approach preserves manufacturing precision while reducing harmful effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IgE epitope-like peptides effectively prevent allergic reactions and systemic adverse events during immunotherapy and medical interventions by blocking allergen-induced effector cell activation, providing a safer and more effective treatment for peanut allergy.
Implementation Method 1
IgE epitope-like peptides which have ability to bind to allergen specific IgE paratopes
Implementation Method 2
prevent degranulation and secretion of mediators of allergic inflammation from effector cells
Data Source
AI summary
The present invention relates to IgE epitope-like peptides which have ability to bind to allergen specific IgE paratopes. Said allergen specific IgEs are bound to effector cells of allergic patients. The IgE epitope-like peptides of the invention cover the paratopes of said IgE bound on effector cells, prevent biding of causative allergen on said IgE on effector cells, and thereby prevent degranulation and secretion of mediators of allergic inflammation from effector cells, after contact with the causative allergen. The present invention relates to the methods of using such IgE epitope-like peptides for therapy of allergic reaction. Said allergic reaction is caused by exposure to the causative allergen.